Quality improvement in neurology: Amyotrophic Lateral Sclerosis Quality Measures

Robert G. Miller, Benjamin Rix Brooks, Rebecca J. Swain-Eng, Robert C. Basner, Gregory T. Carter, Patricia Casey, Adam B. Cohen, Richard Dubinsky, Dallas Forshew, Carlayne E. Jackson, Ed Kasarskis, Nicholas J. Procaccini, Mohammed Sanjak, Fredrik P. Tolin

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations
Original languageEnglish
Pages (from-to)165-168
Number of pages4
JournalAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Issue number3-4
StatePublished - Jun 2014

Bibliographical note

Funding Information:
Dr. Miller has received research support from the Muscular Dystrophy, and is a consultant for Cytokinetics, Neuraltus, and Asubio pharmaceuticals. Dr. Brooks has received funding and/or research grants from AB Science, Acorda, ALS Therapy Alliance, Asubio, Avanir., Biogen Idec, Bristol-Myers Squibb, Cytokinetics, GlaxoSmithKline, Knopp Bioscience, Muscular Dystrophy Association, Neu-raltus, NINDS Clinical Research Consortium, QuestCor, and Teva. Ms. Swain-Eng is a full-time employee of the American Academy of Neurology. Dr. Basner is Principal Investigator of a Muscular Dystrophy Association grant,Opto-Electronic Plethysmography (OEP): A novel non-invasive quantitative assessment of lower rib cage paradox and use of accessory muscles in patients with amyotrophic lateral sclerosis; Site Investigator and Sleep Protocol Subcommittee member of an NHLBI/NIH grant, Sleep-Disordered Breathing During Pregnancy and Risks to Cardiovascular Health; and co-investigator of the following: R01HL103676-01A1 NIH/NHLBI; Subclinical Interstitial Lung Disease in MESA; R01HL093081 NIH/NHLBI; Pulmonary Vascular Changes in Early COPD; and InterMune PIPF-016: a randomized, double-blind, placebo-controlled, phase 3 study of the efficacy and safety of Pirfenidone in patients with Idiopathic Pulmonary Fibrosis (IPF). Dr. Carter reports no disclosures. Ms. Casey is a full-time employee of Northwestern Medical Faculty Foundation, Department of Neurology. Dr. Cohen reports no disclosures. Dr. Dubinsky reports disclosures for relationships with Allergan Pharmaceuticals, NIH, and AHRQ. Ms. Forshew is a consultant for Questcor and Asubio Pharmaceuticals. Dr. Jackson has received research support from Knopp Pharmaceuticals, Biogen Idec, and Cytoki-netics. Dr. Kasarskis is a consultant for Asubio Pharmaceuticals and ATSDR. Dr. Procaccini reports no disclosures. Dr. Sanjak reports no disclosures. Dr. Tolin reports no disclosures.

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Quality improvement in neurology: Amyotrophic Lateral Sclerosis Quality Measures'. Together they form a unique fingerprint.

Cite this